FDA Guides Drug Makers on Rare Blood Disorder Treatments
Published Date: 7/2/2025
Notice
Summary
The FDA just dropped a draft guide to help drug makers create new treatments for myelodysplastic syndromes (MDS), a group of blood disorders. This guide focuses on drugs that actually change the disease, not just ease symptoms. If you’re in the drug biz, this means clearer rules for clinical trials and faster paths to approval, so get ready to innovate and bring better MDS treatments to patients!
Analyzed Economic Effects
3 provisions identified: 1 benefits, 2 costs, 0 mixed.
FDA guidance on MDS trial design
The FDA released a draft guidance to help drug and biological product sponsors design clinical development programs and trials that support an indication for treatment of myelodysplastic syndromes (MDS). The guidance explains FDA's current thinking about overall development programs and clinical trial designs specifically for disease‑modifying MDS treatments.
Supportive-only MDS drugs excluded
The draft guidance applies only to products considered disease‑modifying and does not cover products considered supportive only (for example, erythropoiesis‑stimulating agents). If you develop supportive‑only MDS products, this guidance does not provide FDA's recommendations for your development program.
Certain myeloid neoplasms not covered
The guidance will not address drug development for MDS/myeloproliferative neoplasms such as chronic myelomonocytic leukemia, which the FDA considers a separate class of myeloid neoplasms. Sponsors developing drugs for those separate neoplasms should not expect this guidance to apply to their programs.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-16939, GNT USA, LLC.; Filing of Color Additive Petition
The Food and Drug Administration (FDA or we) is announcing that we have filed a petition, submitted by GNT USA, LLC., c/o Exponent, Inc., proposing that we amend our color additive regulations to provide for the safe use of safflower (Carthamus tinctorius L.) extract as a color additive in various foods at levels consistent with good manufacturing practices.
2026-16942, Food Additives Permitted in Feed and Drinking Water of Animals; Chromium DL-methionine Chelate
The Food and Drug Administration (FDA, we, or the Agency) is amending the regulations for food additives permitted in feed and drinking water of animals to provide for the safe use of chromium DL- methionine chelate as a nutritional source of chromium in cattle feed. This action is in response to a food additive petition filed by Zinpro Corp.
2026-16944, Gardenia Blue Interest Group; Filing of Color Additive Petition
The Food and Drug Administration (FDA or we) is announcing that we have filed a petition, submitted by Gardenia Blue Interest Group (GBIG or petitioner), c/o Exponent, Inc., proposing that we amend our color additive regulations to expand the safe use of gardenia (genipin) blue in various foods at levels consistent with good manufacturing practice. The petition also proposes to lower the specification for arsenic in gardenia (genipin) blue.
Previous / Next Documents
Previous: 2025-12294, Agency Information Collection Activities: Comment Request
The Social Security Administration wants your thoughts on how they collect info for a study about helping homeless people find housing and jobs. They’re checking if their questions are clear, useful, and not too much work for folks to answer. If you want to share your ideas, do it by August 1, 2025—your input could help improve the process without costing extra time or money.
Next: 2025-12298, Rescission of Office of the Assistant Secretary for Public and Indian Housing; Voter Registration Notice
HUD is canceling a 1996 rule that told public housing groups how to help residents register to vote. This change affects Public Housing Agencies and means they no longer have to follow those old voter registration guidelines. No new costs or deadlines are involved—just a clean update to simplify things.